Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study
Phase 4
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024552
- Lead Sponsor
- Hokkaido University Graduate School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who were taking weekly GLP-1 receptor agonist at the time of obtaining informed consent 2)Patients who have experienced severe diabetic ketosis, diabetic coma, or past history of pre-coma within six months 3)Patients with pregnancy or lactation 4)Patients who are taking systemic corticosteroid 5)Type 1 diabetes 6)Patients with severe infection, pre or post operation and severe trauma 7)Patients with severe liver dysfunction 8)Patients with severe renal dysfunction 9)Patients who are deemed to be unsuitable by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The score of Diabetes Treatment Satisfaction Questionnaire (DTSQ)
- Secondary Outcome Measures
Name Time Method 1)The score of Diabetes Therapy Related Quality of life (DTR-QOL) 2)Plasma glucose and HbA1c 3)Body weight and body mass index (BMI) 4)Blood test 5)The assessment of safety: frequency of hypoglycemia, digestive symptom, and so on